Verition Fund Management’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-11,300
Closed -$906K 2820
2025
Q4
$906K Sell
11,300
-12,916
-53% -$868K ﹤0.01% 2230
2025
Q3
$1.18M Sell
24,216
-7,583
-24% -$469K ﹤0.01% 2400
2025
Q2
$2.37M Buy
+31,799
New +$2.11M 0.01% 1793
2025
Q1
Sell
-4,381
Closed -$342K 3475
2024
Q4
$342K Buy
4,381
+1,411
+48% +$113K ﹤0.01% 2703
2024
Q3
$239K Sell
2,970
-3,415
-53% -$276K ﹤0.01% 2775
2024
Q2
$528K Buy
6,385
+4,005
+168% +$352K ﹤0.01% 2024
2024
Q1
$203K Sell
2,380
-290
-11% -$22.8K ﹤0.01% 2494
2023
Q4
$228K Buy
2,670
+290
+12% +$25.1K ﹤0.01% 1952
2023
Q3
$213K Buy
2,380
+26
+1% +$2.32K ﹤0.01% 1943
2023
Q2
$200K Sell
2,354
-1,426
-38% -$121K ﹤0.01% 1860
2023
Q1
$313K Buy
+3,780
New +$306K ﹤0.01% 1496
2021
Q2
Sell
-7,436
Closed -$825K 1992
2021
Q1
$825K Buy
+7,436
New +$920K 0.01% 662
2020
Q1
Sell
-8,238
Closed -$947K 792
2019
Q4
$947K Buy
+8,238
New +$997K 0.02% 468
2018
Q4
Sell
-3,917
Closed -$449K 994
2018
Q3
$449K Sell
3,917
-12,198
-76% -$1.26M 0.02% 878
2018
Q2
$1.45M Buy
+16,115
New +$1.36M 0.09% 278
2017
Q4
Sell
-5,738
Closed -$257K 998
2017
Q3
$257K Sell
5,738
-5,702
-50% -$237K 0.02% 948
2017
Q2
$452K Buy
+11,440
New +$470K 0.04% 478
2017
Q1
Sell
-5,712
Closed -$230K 1284
2016
Q4
$230K Buy
+5,712
New +$215K 0.02% 971

Other funds holding HAE

Verition Fund Management's HAE Position: Q1 2026 in Review

Verition Fund Management sold out of Haemonetics (HAE) in Q1 2026, closing a stake of 11,300 shares — an estimated $906K sold.

Verition Fund Management first reported a position in HAE in Q4 2016 and held it in 18 quarters. The position peaked at $2.37M in Q2 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Verition Fund Management reported no remaining Haemonetics position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 11,300 Haemonetics shares in Q1 2026, an estimated $906K.
  • Verition Fund Management first reported a position in Haemonetics in Q4 2016 and held it in 18 quarters.
  • Verition Fund Management's Haemonetics position peaked at $2.37M in Q2 2025.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.